ITM Isotope Technologies Munich has secured an exclusive global license for the clinical and commercial development of Debiopharm’s cancer imaging and treatment pair ITM-91/ITM-94D.
Formerly known as Debio 0228/0328, ITM-91/ITM-94D targets a surface protein expressed on solid tumors. ITM-91 is a lutetium-177-labeled radioligand therapeutic compound and ITM-94D is a gallium-68-labeled imaging agent. The pair is being investigated in the phase I/II clinical trial in patients with clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.
Under the agreement, Debiopharm will receive payments of approximately $331 million, as well as commercial milestones and royalties on potential future sales, ITM said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
